The Food and Drug Administration approved two breakthrough-designated oncologics this week, including its fastest novel approval of 2020: Seattle Genetics Inc.’s Tukysa (tucatinib) for HER2-positive breast cancer.
New product submission news was light, headlined by Regeneron Pharmaceuticals Inc.’s Ebola virus therapy and a combined oral contraceptive...